Gilead's Kite builds cell therapy manufacturing quickly even as Yescarta sales grow slowly

So far, Gilead’s Kite Pharma has been buying the viral vector starting material for its CAR-T treatment Yescarta from contractors. But with an expanding pipeline of cell therapies, the company says it is time to be able to produce its own.